MedTrace Logo

Decision Impact Trial of KidneyIntelX

NCT04791358 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2024-04-12

No results posted yet for this study

Summary

The current trial is designed to evaluate how the results of KidneyIntelX test impacts on the clinical management of type 2 diabetes patients identified as increased risk for rapid kidney function decline within 5-years.

Conditions

  • Diabetic Kidney Disease

Interventions

DIAGNOSTIC_TEST

KidneyIntelX

KidneyIntelX is an in-vitro diagnostic that enables accurate risk prediction of progressive decline in kidney function and kidney failure in patients with type 2 diabetes and existing CKD at stages 1-3 (eGFR of 30 to 59 ml/min/1.73m2, or eGFR ≥ 60 ml/min/1.73m2 and uACR ≥ 30 mg/g).

Sponsors & Collaborators

  • Renalytix AI, Inc.

    lead INDUSTRY

Eligibility

Min Age
23 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-01
Primary Completion
2024-11-01
Completion
2024-12-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04791358 on ClinicalTrials.gov